Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine.
Vaccine
; 20(23-24): 2866-72, 2002 Jul 26.
Article
in En
| MEDLINE
| ID: mdl-12126896
ABSTRACT
The duration of immunity provided by a feline leukemia virus (FeLV) vaccine, Leukocell 2, was determined. Kittens were vaccinated when 9 and 12 weeks of age and were challenged 12 months later with FeLV-A/Glasgow-1. An oronasal challenge protocol without corticosteroid enhancement was developed in order to induce a persistent viraemia in a high proportion of adult cats. Fourteen of 18 (80%) of the vaccinated cats challenged in this way remained non-viraemic while 9/15 (60%) of age-matched controls became persistently infected, a preventable fraction of 63%. This difference was statistically significant (P=0.038). For comparison, 10 of 12 (83%) 15-17-week-old kittens challenged in the same way became persistently infected, confirming the relative resistance of adult animals to FeLV. Tests for virus neutralising and anti-feline oncornavirus-associated cell membrane antigen (FOCMA) antibodies suggested that the former were more important than the latter in protection. Thus, Leukocell 2 protected a significant proportion of cats from FeLV challenge 1 year after primary vaccination as kittens.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tumor Virus Infections
/
Viral Vaccines
/
Cat Diseases
/
Retroviridae Proteins, Oncogenic
/
Leukemia Virus, Feline
/
Retroviridae Infections
Limits:
Animals
Language:
En
Journal:
Vaccine
Year:
2002
Document type:
Article
Affiliation country:
Reino Unido